These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24079645)

  • 1. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
    Ohta A; Ohshige T; Sakai K; Nakamura Y; Tenjin A; Tsukiyama S; Terashima Y; Matsubara F; Kawata T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2013 Dec; 14(17):2315-22. PubMed ID: 24079645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
    Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.
    Arao T; Okada Y; Torimoto K; Sugai K; Otsuka T; Kurozumi A; Tanaka Y
    J UOEH; 2017; 39(1):1-9. PubMed ID: 28331117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
    Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
    Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
    Iwamoto Y; Tajima N; Kadowaki T; Nonaka K; Taniguchi T; Nishii M; Arjona Ferreira JC; Amatruda JM
    Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
    Inoue M
    Expert Opin Pharmacother; 2012 Nov; 13(16):2257-68. PubMed ID: 22994875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
    Ono Y; Kameda H; Cho KY
    Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
    Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
    Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.
    Tani S; Nagao K; Hirayama A
    Drug Res (Stuttg); 2016 Feb; 66(2):94-9. PubMed ID: 26011816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
    Son JW; Lee IK; Woo JT; Baik SH; Jang HC; Lee KW; Cha BS; Sung YA; Park TS; Yoo SJ; Yoon KH
    Endocr J; 2015; 62(12):1049-57. PubMed ID: 26411328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
    Seo C; Sakamoto M; Nishimura R; Tsujino D; Ando K; Morimoto A; Utsunomiya K
    Diabetes Technol Ther; 2013 May; 15(5):378-85. PubMed ID: 23634671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
    Takahara M; Shiraiwa T; Katakami N; Matsuoka TA; Shimomura I
    Diabetes Technol Ther; 2014 Oct; 16(10):633-9. PubMed ID: 24949654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.